12,076 Shares in AnaptysBio, Inc. (NASDAQ:ANAB) Purchased by SG Americas Securities LLC

SG Americas Securities LLC purchased a new position in AnaptysBio, Inc. (NASDAQ:ANAB) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 12,076 shares of the biotechnology company’s stock, valued at approximately $405,000.

A number of other hedge funds also recently bought and sold shares of ANAB. Frazier Life Sciences Management L.P. boosted its stake in AnaptysBio by 140.7% in the 2nd quarter. Frazier Life Sciences Management L.P. now owns 2,165,591 shares of the biotechnology company’s stock worth $54,270,000 after purchasing an additional 1,265,891 shares in the last quarter. StemPoint Capital LP lifted its stake in AnaptysBio by 499.0% during the 1st quarter. StemPoint Capital LP now owns 269,548 shares of the biotechnology company’s stock valued at $6,070,000 after acquiring an additional 224,548 shares during the period. Assenagon Asset Management S.A. lifted its stake in AnaptysBio by 38.2% during the 2nd quarter. Assenagon Asset Management S.A. now owns 306,633 shares of the biotechnology company’s stock valued at $7,684,000 after acquiring an additional 84,795 shares during the period. Platinum Investment Management Ltd. bought a new position in AnaptysBio during the 1st quarter valued at about $1,490,000. Finally, Cubist Systematic Strategies LLC bought a new position in AnaptysBio during the 2nd quarter valued at about $1,360,000.

AnaptysBio Stock Up 1.4 %

NASDAQ ANAB opened at $35.18 on Friday. AnaptysBio, Inc. has a 52 week low of $13.36 and a 52 week high of $41.31. The firm has a market capitalization of $961.08 million, a P/E ratio of -5.73 and a beta of -0.29. The company has a 50-day moving average price of $35.39 and a 200-day moving average price of $29.18.

AnaptysBio (NASDAQ:ANAB) last released its earnings results on Monday, August 5th. The biotechnology company reported ($1.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.89) by ($0.82). The firm had revenue of $10.97 million during the quarter, compared to analysts’ expectations of $25.85 million. AnaptysBio had a negative return on equity of 255.68% and a negative net margin of 558.25%. As a group, equities research analysts anticipate that AnaptysBio, Inc. will post -6.84 EPS for the current year.

Insider Buying and Selling

In related news, insider Paul F. Lizzul sold 1,500 shares of the stock in a transaction that occurred on Monday, September 23rd. The shares were sold at an average price of $38.67, for a total value of $58,005.00. Following the completion of the sale, the insider now directly owns 15,398 shares of the company’s stock, valued at approximately $595,440.66. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In related news, major shareholder Ecor1 Capital, Llc acquired 273,972 shares of the business’s stock in a transaction on Wednesday, August 14th. The stock was acquired at an average cost of $36.50 per share, with a total value of $9,999,978.00. Following the acquisition, the insider now directly owns 7,794,996 shares in the company, valued at $284,517,354. This represents a 0.00 % increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Paul F. Lizzul sold 1,500 shares of the stock in a transaction that occurred on Monday, September 23rd. The shares were sold at an average price of $38.67, for a total transaction of $58,005.00. Following the sale, the insider now directly owns 15,398 shares of the company’s stock, valued at approximately $595,440.66. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 22,440 shares of company stock valued at $892,936. 33.70% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on ANAB. Truist Financial upped their target price on shares of AnaptysBio from $20.00 to $30.00 and gave the company a “hold” rating in a research note on Thursday, August 15th. HC Wainwright restated a “buy” rating and set a $55.00 target price on shares of AnaptysBio in a research note on Wednesday, August 14th. JPMorgan Chase & Co. upped their target price on shares of AnaptysBio from $69.00 to $75.00 and gave the company an “overweight” rating in a research note on Wednesday, August 7th. Finally, Wedbush restated an “outperform” rating and set a $42.00 target price on shares of AnaptysBio in a research note on Thursday, September 26th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and nine have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $51.10.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.